To investigate the association between SPI1 expression and immunotherapy efficacy in RCC, IHC staining of SPI1 was performed in six patients with RCC who had received at least four cycles of pembrolizumab plus axitinib at our center (Fig. 5a, b). This evidence concerns the gene SPI1 and renal cell carcinoma.